Cancer Immunotherapies in Finland - New report now available!

Cancer IO’s new report Cancer Immunotherapies in Finland was published in Helsinki University Think Corner on 9 March 2022. 

The objective of the report is to provide under­standing of the current state of the adoption and use of IO ther­apies in Finland com­pared to the other Nordics coun­tries, and the factors affecting it.

According to the IQVIA data for the period of 2016-2020, PD-1/PD-L1 inhib­itors are sold in higher amounts in the other Nordic coun­tries than in Finland. 


The report includes the description of the pro­cesses involved in the adoption of new cancer treat­ments, and the fin­ancing and pro­curement of medi­cines in Finland and the Nordics.

The report is based on expert inter­views with clini­cians and hos­pital man­agement, rep­res­ent­atives of the phar­ma­ceutical industry, and reg­u­latory authorities/​national bodies. The report focuses on the Finnish envir­onment, but also briefly describes the sim­il­ar­ities and dif­fer­ences of medicine eval­u­ation, fin­ancing, and pro­curement pro­cesses between the Nordic countries.

The report includes Cancer IO’s recom­mend­a­tions on how to move forward with IO treat­ments while ensuring cost-effective use and quick access to new medi­cines with equity for patients across regions and diseases.

You can read and download the report via this link.

Soita 000 000 0000